It takes a lot to impress a mature skin beauty writer – but this anti-ageing cream won me over
Celebrity dermatologist Dr. Howard Murad was among the first dermatologists to start selling clinical skincare products to the general public. Today, his anti-ageing products are so well-loved and trusted that Murad is the number one dermatologist-founded skincare brand in the States.
The brand's marketing makes much of the claim that it only uses 'scientifically proven formulas' to create its products, but it's hard to measure up to that promise. When I saw that the brand launched a range of four new SPF moisturisers, with a high level of sunscreen and high-performance actives, I had to see if it really lived up to the hype.
Leading the pack is the Murad superactive moisturiser SPF50: brightening, an update to the essential-C day moisturise SPF30 (£69, Marksandspencer.com) with a new formula and a new look. This vitamin C-loaded day cream promises to act like a 3-in-1 moisturiser, skin-brightener and sunscreen all in one, and it certainly lives up to the claim. It's so good it's earned itself the top spot in my guide to the best anti-ageing day creams.
How I tested
To put the new SPF moisturiser to the test, I've been trialling it for six weeks in place of my daily serum, moisturiser and SPF. This was through two heat waves when UV levels were high. During testing, I assessed the moisturiser using the following criteria.
Texture: I noted how the formula felt on the skin. Did it feel greasy and heavy, or was it more lightweight?
Hydration: And, as a moisturiser, its formula should be hydrating, so I noted how hydrated my skin felt. Additionally, I assessed how well the formula sat beneath my make-up, and whether it left a white cast, as SPFs sometimes can.
Results: I looked at how well the cream rejuvenated my skin. Specifically, whether it brightened and evened my skin tone, and had any effect on dark spots, as these are the effects the brand claims the product will have. At the same time, I noted any skin irritation.
Ease of use: Murad has introduced new packaging, so I assessed if, and how, this helped with ease of application.
Why you can trust IndyBest reviews
Sabine Wiesel is a beauty journalist with years of experience trialling and recommending skincare to IndyBest readers. As a woman in her 40s, she has reviewed plenty of neck creams, retinol eye creams and similar products formulated to address the signs of ageing, such as fine lines, dullness and dark spots. With this in mind, she knows which actives to look for, and has a wealth of relevant testing experience. Having tried many anti-ageing day creams for our round-up of the best, Sabine named Murad's superactive moisturiser SPF50 the best on test. This is her full, honest review.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
3 minutes ago
- Reuters
Vertex's trial failure, scrapped study cloud pain drug push; shares slump
Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of its approved pain drug, sending its shares down 14.4% after the bell. The company (VRTX.O), opens new tab has been diversifying into gene therapies and non-opioid painkillers as it looks to reduce its reliance on cystic fibrosis drugs, a market it dominates. Unlike opioids, which trigger the brain's reward centers, making them an addiction risk, Vertex's drugs block pain signals at the origin, providing a lucrative opportunity for the company. The next-generation non-opioid painkiller, called VX-993, reduced pain by 74.5 points over 48 hours, compared with 50.2 points in the placebo group, but the difference was not statistically significant, Vertex said. The company tested acute pain reduction in patients who had bunionectomy, a surgery to correct deformed bones of the big toe and foot. The drug was found to be generally safe, with most side effects being mild to moderate and no serious problems linked to the painkiller, the company said. Wall Street analysts and investors have been keenly watching the results of the trial, as Vertex seeks to expand beyond Journavx, its non-opioid approved by the U.S. Food and Drug Administration in January for acute pain. Separately, Vertex also said it would not start a study for Journavx to treat a type of nerve pain in the lower back and legs following discussion with the FDA. Leerink Partners analyst David Risinger said Vertex's pain portfolio updates were "disappointing," despite reporting second-quarter results that were above expectations. Vertex plans to prioritize testing of, and later seeking approval for, Journavx to treat a type of nerve pain in diabetic patients. It will also seek to secure approval for other types of nerve pain, the company said in its earnings press release.
The Independent
32 minutes ago
- The Independent
Colorectal cancer rates in the US have increased ‘steeply', research finds
Research indicates a steep rise in colorectal cancer rates among younger adults in the U.S., with a 50 percent relative increase observed between 2021 and 2022. The recommended screening age was lowered from 50 to 45 in 2021 to encourage earlier detection, as early onset cases have nearly doubled in young adults under 55 over the past decade. Colorectal cancer is the third leading cause of cancer deaths in the U.S., with over 154,000 new cases projected for this year. While theories such as poor nutritional health and gut toxins are being explored, researchers have not yet identified a definitive cause for the surge in cases. Experts predict that by 2030, colorectal cancer could become the leading cause of cancer death for individuals under 50, highlighting the need for increased public awareness and screening.
The Independent
2 hours ago
- The Independent
Health warning issued as source of serious bacteria outbreak revealed
Public health officials have issued a warning regarding an outbreak of Campylobacter and E. coli linked to raw milk from an unnamed farm in Florida. The outbreak has affected 21 individuals, including six children under 10, resulting in seven hospitalisations and two severe complications. The Florida Department of Health expressed concerns about sanitation practices at the implicated farm, noting that raw milk is only legally sold for non-human consumption in the state. Federal health agencies, including the CDC and FDA, strongly advise against consuming raw milk due to significant health risks from various pathogens, emphasising that pasteurisation eliminates these dangers. Despite scientific consensus on the risks, raw milk has gained popularity among some groups, with Health and Human Services Secretary Robert F. Kennedy Jr. being a consumer, though his administration has not delivered the regulatory changes raw milk advocates hoped for.
